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ABSTRAK 
 
Pengurusan pesakit yang membentuk kerintangan imun terhadap platelet adalah mencabar. 
Salah satu kaedah yang ada adalah menerusi pembekalan platelet yang serasi menerusi ujian 
keserasian platelet. Prosedur ujian yang digunakan iaitu “Solid Phase Red Cell Adherence 
(SPRCA)”  berfungsi dengan baik sebagai ujian keserasian platelet. Walaubagaimanapun, 
terdapat beberapa kekurangan yang menyebabkan ia kurang sesuai digunakan dalam beberapa 
keadaan. SPRCA adalah ujian secara manual dan melibatkan intepretasi keputusan ujian dan 
dokumentasi secara manual sepenuhnya. Disebabkan penggunaan “microplate” berbentuk U, 
ujian keserasian ini perlu dijalankan secara berkelompok dan tidak sesuai digunakan untuk 
bilangan ujian yang sedikit. Tambahan pula, operasi manual dan kaedah ujian yang rumit pula 
boleh menyumbang kepada proses yang berat sebelah. Oleh itu, kecekapan penguji menjadi 
faktor yang penting. Disebabkan kelemahan-kelemahan ini, terdapat keperluan untuk mencari 
kaedah ujian lain yang boleh mengatasi kelemahan SPRCA dan seterusnya diimplimentasi ke 
dalam perkhidmatan tabung darah.  “Platelet Immunofluorescence Test (PIFT)” adalah ujian 
yang menggunakan prinsip ujian yang sama seperti SPRCA tetapi menggunakan flow citometer 
untuk menganalisis keputusan ujian. Di dalam kajian ini, PIFT diuji untuk mencari kekuatan dan 
kelebihannya sebagai ujian keserasian platelet, terutamanya pada aspek kualiti prestasi dan 
ketersediaan untuk operasi makmal. Sebanyak 20 penderma aferesis telah didaftarkan ke dalam 
kajian ini, dan profil genotip HPA mereka di uji menggunakan ujian PCR-SSP. 11 serum kawalan 
daripada 4 kategori “platelet reactive antibody” telah dimasukkan ke dalam kajian dan jenis 
antibodinya dipastikan. Ujian keserasian dijalankan menggunakan suspensi platelet penderma 
yang baru disediakan, terhadap serum. Setiap ujian keserasian di ulang semula, sama ada pada 
hari pertama, kedua atau ketiga selepas hari penyediaan suspensi platelet.  Ramalan keputusan 
ujian keserasian di buat berdasarkan maklumat genotip penderma dan jenis antibodi pada 
serum. Keputusan ujian ramalan ini kemudiannya dibandingkan dengan keputusan sebenar 
xiv 
 
ujian keserasian yang dilakukan. Keputusan ujian kemudiannya diterjemahkan kepada ‘betul’ 
atau ‘palsu’ dan ‘serasi’ atau ‘tidak serasi’, seterusnya dianalisis dengan statistik yang sesuai 
untuk jenis keputusan dwi-data. Daripada 20 penderma dan 11 serum kawalan, sebanyak 237 
ujian keserasian telah dijalankan. Dalam mengenalpasti ketidakserasian, PIFT telah menujukkan 
keupayaan untuk mengesan sebanyak 91.2%, dengan ketepatan sebanyak 62.4% dan 
ketidakserasian palsu sebanyak 34.2%. Sebaliknya, semasa mengesan keserasian, pengesanan 
hanyalah sebanyak 65.8% dengan ketepatan sebanyak 93.2% dengan keserasian palsu hanyalah 
sebanyak 8.8%. Ini menunjukkan prestasi yang menakjubkan sebagai ujian keserasian platelet 
dimana ia mengesan lebih banyak ketidakserasian palsu untuk meningkatkan keselamatan dan 
pada masa yang sama memberikan keputusan serasi yang tepat. Tambahan pula, PIFT boleh 
dijalankan ke atas bilangan sampel yang sedikit, dan boleh menghasilkan keputusan ujian 
janaan komputer, dimana kedua-dua ciri ini tidak didapati pada SPRCA. Kos ujian PIFT hanyalah 
sekitar RM3.50 setiap satu. Ujian ini adalah mudah, murah dan boleh dipercayai. Berdasarkan 
kajian ini, PIFT telah menunjukkan prestasi yang mengagumkan sebagai ujian keserasian 
platelet. Ia menawarkan kelebihan yang istimewa dan boleh diserap ke dalam perkhidmatan 
tabung darah untuk proses pembekalan platelet serasi kepada pesakit yang membentuk 
kerintangan imun terhadap platelet. 
 
 
 
 
 
 
 
 
xv 
 
ABSTRACT 
 
Managing patient with immune mediated platelet refractoriness can be very challenging. One 
of the approach is by selecting compatible platelet via crossmatch test. The existing protocol ; 
Solid Phase Red Cell Adherence (SPRCA) assay works very well as a platelet crossmatch assay. 
However, it have some limitations that make it unsuitable to be used in certain situation. SPRCA 
is a fully manual test with manual result interpretation and documentation. It utilizes U-shape 
microplate and run on batches of samples. Due to manual operation and laborious procedure, 
there are chances of bias to occur, therefore competency and skill of operator becomes an 
important confounding factor. Furthermore, SPRCA is not suitable for single or low throughput 
crossmatch. Due to these restrictions, there is a need to search for another platelet crossmatch 
protocol that can overcome the limitations of SPRCA thus be implemented in blood centre 
setting. Platelet Immunofluorescence Test (PIFT) assay is an assay that runs on similar principle 
(whole platelet based assay) as SPRCA, except that it utilizes flow cytometer for result analysis. 
In this study, PIFT is being challenged to discover its strength and advantages in performing 
platelet crossmatch test, particularly on qualitative performance and feasibility aspect on 
operational service.   20 platelet apheresis donors were enrolled in this study and their HPA 
genotype were determine by PCR-SSP. 11 known control serums from 4 category of platelet 
reactive antibodies were recruited and antibody specificity were determined. Crossmatch were 
performed on freshly prepared donor’s platelet suspension against serum. Each crossmatch 
were then repeated once either on day-1, day-2 or day-3 of platelet suspension preparation. 
The predicted compatibility of donor crossmatched to serum were established based on the 
donor’s genotype and antibody specificity, and were compared to the actual crossmatch result 
obtained. Compatible and incompatible observation were then translated as true and false of 
positive and negative outcomes. The results were then statistically analysed with parameters 
suited for qualitative binomial data. From all 20 donors and 11 serums, 237 total crossmatching 
xvi 
 
have been performed. In detecting incompatibility, PIFT has demonstrated the ability to detect 
as high as 91.2%, with accuracy of 62.4% and false positive of 34.2%. Conversely, when detecting 
compatibility, it detects only 65.8% with the accuracy as high as 93.2% with low false negative 
of 8.8%. This shows an outstanding performance of crossmatching test where it detect more 
false positive to enhance safety, in the same time gives accurate compatible result. Furthermore, 
PIFT can be done with single or low throughput crossmatch, and able to generate computer-
based-results which a feature that is lacking in SPRCA. PIFT cost about RM3.50 per test. It is a 
simple, cheap and reliable assay. PIFT shows an outstanding performance as a platelet 
crossmatch assay. It offers great advantages and are feasible to be implemented in a blood 
banking setting for the provision of compatible platelet supply for the immune mediated 
thrombocytopenic patient.  
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Chapter 1 
INTRODUCTION 
 
1.1 Literature Review 
1.1.1 The platelet cell  
Platelets, are the smallest blood cells that can be found in the blood circulation. At resting phase, 
platelet shaped like a discoid lens and can reach the size of 3-5µm at their greatest diameter 
(Craig H. Fletcher, 2015). However, the size can significantly increase with the formation of 
pseudopods when they get activated. Despite of their small size that makes them appear as 
insignificant, they are very crucial to life and are extensively studied for their complex physiology 
(Rodak et al., 2007).  
 
Platelet are also known as thrombocyte. They are anucleated cells and have short life span of 
around 10 days. Since it is short, platelet need to be constantly generated from the 
megakaryocytes in order to maintain a normal platelet level (Cho, 2015). The cell production is 
regulated by the thrombopoietin hormone and other cytokines. When a megakaryocyte receives 
response from these thrombopoiesis signals, they release platelet into the blood circulation, with 
average about 2,000 to 10,000 of platelets per single megakaryocytes (Kaushansky, 2008).  
 
In normal healthy individual, platelet circulates the blood stream in a great amount ranging from 
150 to 400 x 109/L cell count. In situation when there is an overwhelming of platelet, the 
haemostatic balance is disturbed and this may lead to blood clotting disorder. This condition is 
called thrombosis. Conversely, if the platelet count is low, it can trigger spontaneous abnormal 
bleeding. The low platelet count condition is known as thrombocytopenia. Both conditions can 
be life threatening and may cause significant morbidity and even mortality to the patient, however 
thrombocytopenia are more common. It may be resulted from suppression or failure of the bone 
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marrow to produce the platelet cells, or more commonly through shortened platelet survival due 
to increase in vivo platelet destruction (Delicou and Bellia, 2015, Lochowicz and Curtis, 2011).  
 
Platelet is well known for its critical involvement in haemostasis with the ultimate goal to crosslink 
fibrinogen to form fibrin clot thus stopping the bleeding. Later discovery have reveal that they 
also have role in innate immunity, inflammatory and tumour metastasis (Sorrentino et al., 2015). 
In active bleeding situation where the autologous platelet is low, transfusion of platelet is 
necessary to reach the haemostatic control of bleeding. Apart from that, in thrombocytopenic 
patient, platelet is often transfused as prophylaxis treatment before starting any invasive 
treatment procedure to the patient (McCullough, 2010). In similarity to the red and white blood 
cells, platelet also express many antigens on the platelet surface, that could give rise to 
immunology issues which could hinder the therapeutic effects of a  platelet transfusion. 
 
 
 
Figure 1 : Platelet morphology.  
Picture adapted from The University of Georgia, College of Veterinary Medicine website.  
Platelet on the left is at resting stage and platelets on the right is at activated stage.  
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1.1.2 Platelet alloantigen and alloimmunization  
There are two diﬀerent categories of clinically relevant platelet alloantigens. Antigens that is being 
shared with other blood cells and tissues are referred to as “Type 1 antigen”. The antigens belongs 
to this type of group is the ABH antigen system that is predominantly found on red blood cells. 
Another group of antigen are the glycoprotein antigens of the HLA Class 1 which is abundantly 
found on all nucleated cells. The second category of the platelet alloantigen is the                                      
“Type 2 antigen” that are specifically found on platelets (Santoso, 2003, Mueller-Eckhardt et al., 
1990), thus are called the platelet specific antigen or the Human Platelet Antigen (HPA). 
  
Antigen are characterised by the capability to elicit an antibody production.  When the immune 
cells of an individual was exposed to a foreign alloantigen, the interaction will provoke 
sensitization, and later produce the specific alloantibody toward the specific antigen.                          
Upon second exposure to the same alloantigen, the antibody will recognize the specific antigen, 
form linkage binding and coat the platelet surface. The antibody-coated platelet will soon lead to 
immune mediated platelet destruction where they are either being destroyed through the 
complement activation, or through the phagocytosis activity in the reticuloendothelial system 
(RES). In the blood circulation, as the antibody-coated platelets pass through the spleen and liver 
of the RES, the fragment crystallisable (Fc) portion of the antibody molecules will engaged to the                                
Fc-receptors on the surface of monocytes or macrophages in these organs. This will finally lead 
to platelet destruction and clearance (Lochowicz and Curtis, 2011). 
 
Without the capability to induce the formation of alloantibody, a genetically determine protein or 
carbohydrate will not be called as an “antigen”. This will be further explain in paragraph 1.1.2.3 
the human platelet antigen group. 
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1.1.2.1 The ABH blood group on platelet 
In blood transfusion service, the inventory management need to be highly efficient in order to 
keep good coordination of blood stock and blood supply. The pressure mount up with the need 
to keep low expiry rate of blood, especially for the precious and expensive apheresis unit that only 
have the shelf life of 5 days. In many blood centres, platelet is transfused without regard to the 
ABO compatibility, by giving priority to the age of the platelet unit (Kelsey, 2003, Bethasda, 2005). 
It is widely thought that the amount of the A and B antigen expressed on platelet is too little to 
significantly affect the survival of the ABO-incompatible platelet in vivo, therefore it is a common 
practice to transfuse the ABO incompatible platelet (Curtis et al., 2000).  
 
Platelet express the A, B and H antigens on sugar moieties attached to all platelet glycoprotein 
(Cooling, 2007), however, the majority of ABH is expressed on GPIIb and the platelet endothelial 
cell adhesion molecule (CD31 and PECAM-1) (Curtis and McFarland, 2014, Curtis et al., 2000). 
Apart from the ABH antigens, P, Lewis a and I antigen also appear to be expressed on platelet 
membrane (Dunstan and Simpson, 1985, Marwaha and Sharma, 2009). However, Rh antigens, 
which reside on glycoprotein involved in ammonia transport across cell membrane, do not appear 
to be expressed on human platelets. Neither were the Duffy, Kidd, Kell, and Lutheran antigens 
(Dunstan et al., 1984). While A1 group is well expressed on platelet that range from 2,100 to 16,000 
copies per cell, A2 group express small or no A antigen on platelet (Cooling et al., 2005, Curtis et 
al., 2000). B expression on platelet was discovered to be weaker than A1 (Cooling et al., 2005, Heal 
et al., 1989). Since A2 donors have little or no A antigen on platelet membrane, they are 
compatible with major ABO-mismatch platelet and therefore can be noted as universal platelet 
donor. This approach have been adopted in Norway where A2 platelet is pooled under the  
universal group of platelet (Novotny, 2005). About four years later, Julmy and colleagues had done 
an extensive study on 400 patients of ABO identical, major and minor mismatch platelet 
transfusion. The result demonstrated that for major mismatch of group A1, the platelet respond 
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was lower as compared to the ABO identical platelet transfusion. Conversely, major mismatch A2 
were as successful as ABO identical transfusion (Julmy et al., 2009) which is in agreement with the 
previous findings on A2 expression.  
 
Ogaswara and coworkers have discovered that the amount of ABH expressed on platelet 
membranes differs between individual where each person can be classified as low-expresser and 
high-expresser group. These ‘high expresser group’ may have an elevated expression of ~20 times 
of normal A or B antigen level (Ogasawara et al., 1993). ABO antibodies reacting with the high 
expresser platelets have been reported to be implicated in NAIT (Curtis et al., 2008).  
 
ABO incompatibility between donor and recipient can be define as major, minor and bidirectional 
mismatch. This much depending on the A and B antigen expression of the platelet, and also the 
natural occurring antibody of the suspended plasma (Yazer et al., 2012). In the early years, scientist 
have reported that, satisfactory increment were obtained with ABO compatible platelet 
(Ogasawara et al., 1993, Skogen et al., 1988, Brand et al., 1986). However, more aggressive studies 
have been done (Stolla et al., 2015) and many reports from different group of researchers have 
been published regarding the observation on poor platelet transfusion increment associated to 
the transfusion of ABO-incompatible blood (Refaai et al., 2011, Inaba et al., 2010, Shanwell et al., 
2009). It is soon to be understood that the A and B antigen on the platelet does have an impact 
on the survival of the transfused platelet as it may lead to premature destruction of the cell.            
This was then followed by change of policy on providing ABO compatible platelet in some 
institution (Stolla et al., 2015). In 2012, Yazer and coworkers attempted to look on the other 
adverse reaction of ABO incompatible platelet transfusion by focusing on 162 recipients who 
develop fever following platelet transfusion. However they have discovered that there is no 
significant association between ABO incompatibility and FNHTR (Yazer et al., 2012).  
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 1.1.2.2 HLA Class 1 on platelet 
HLA Class 1 are very well expressed on platelet, predominantly the HLA-A and HLA-B (Szatkowski 
et al., 1978) with weak expression of HLA-C (Mueller‐Eckhardt et al., 1980). About 2/3 of blood’s 
HLA Class 1 are expressed on platelet and was reported to be of average about 20,000 molecules 
of HLA class I per platelet (Pereira et al., 1988), however, the amount varies amongst individuals 
(Kao et al., 1990, Pereira et al., 1988).  
 
Due to the highly polymorphic characteristics of the HLA, immunization to HLA Class 1 can easily 
occur following transfusion, pregnancy and transplantation. It is reported to be the major  cause 
of immune mediated transfusion refractoriness (McFarland et al., 1997), especially in the multiple 
transfused patient who need long support of transfusion. In oppose to that, the association of 
anti-HLA Class 1 antibody in NAIT cases are still debatable (Taaning, 2000). Although some cases 
of NAIT are probably caused by maternal HLA antibodies reactive with foetal and neonatal 
platelets, it is difﬁcult to implicate the involvement of anti-HLA Class 1 in the pathogenesis of this 
disorder because as many as 30% of multiparous women are immunized against HLA class I 
(Kakaiya et al., 2010, Triulzi et al., 2009), but the majority of them do not give birth to infants with 
thrombocytopenia. 
 
 
1.1.2.3    Platelet specific antigen – Human Platelet Antigen (HPA) 
Human Platelet Antigen (HPA) are the specific antigen found on platelet residing on glycoprotein 
complex on the platelet membrane. To date, 33 HPAs have been identified to be expressed on six 
different platelet glycoprotein (Curtis and McFarland, 2014). These glycoproteins are the GPIIb, 
GPIIIa, GPIba, GPIbb, GPIa and CD109. The HPA antigens are numbered according to the order of 
the discovery, with the high frequency antigen is designate as ‘a’ and the antithetical low 
frequency antigen is labelled as ‘b’. Twelve antigens are being clustered into six biallelic group, 
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while the other 21 low frequency antigens are designated as ‘w’ (for workshop) indicating that 
only antibody only toward the ‘b’ antigen has been discovered, but not toward its antithetical 
partner (Curtis and McFarland, 2014). Without the capability to induce the formation of an 
alloantibody, a genetically determine protein or carbohydrate will not be called as an “antigen”, 
thus these antithetical partner “antigens” are not listed in the list of Human Platelet Antigen.  
 
Whilst some HPAs are commonly implicated in immune-mediated thrombocytopenic disorder 
(e.g. HPA-1a in NAIT), other HPAs appear to be less immunogenic and therefore rarely implicated 
(Curtis and McFarland, 2014). Figure 2 below illustrate the platelet glycoprotein (GP) structures, 
GPIIb/IIIa, GPIa/ IIa, GPIb/IX and CD109, and the locations of HPA antigen they express. 
   
 
 
 
Figure 2  :  Platelet glycoprotein (Curtis and McFarland, 2014). 
The above illustration depicted the glycoprotein structure of GPIIb/IIIa, GPIa/IIa, GPIb/IX and 
CD109, with the location of the different human platelet antigen location.  
The list of Human Platelet Antigen is tabulated in appendix 1.  
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1.1.3 Alloimmune thrombocytopenic disorder 
Alloimmunization is related to the composition of antigen in the blood product transfused and 
the immune status of the recipient (Pavenski et al., 2012). Even though platelet alloantigen can be 
divided into three groups, all alloantibodies toward the antigens are called the platelet reactive 
antibodies. These antibodies are the causal for platelet clearance by the mechanism known as 
immune-mediated thrombocytopenia. Disorders caused by the alloimmune-mediated 
thrombocytopenia is the platelet transfusion purpura (PTP), neonatal alloimmune 
thrombocytopenia (NAIT), and platelet transfusion refractoriness (PTR).  
 
1.1.3.1 Post Transfusion Purpura (PTP) 
Post transfusion purpura (PTP) is a rare acquired disorder that occurs about one to two weeks 
following a transfusion of blood products (Shtalrid et al., 2006). It is a rare type of delayed adverse 
reaction triggered by anamnestic immune response (Kaplan, 2002) which eventually lead to 
immune destruction of platelet leading to severe thrombocytopenia. However the pathogenesis 
remain unclear whereby the alloantibody of the patient will not only attack the transfused 
alloantigen-positive platelet, but paradoxically destroy the autologous platelet that is negative for 
the offending antigen (Shtalrid et al., 2006, Kaplan, 2002). PTP is caused specifically by the HPA 
group of antigen and in majority of the cases by anti-HPA-1a. However, the occurrence on anti-
HPA-1a was observed to be associated with HLA class II allele DRB3*0101. This findings has been 
observed in majority of the patients with PTP (Kaplan, 2002, McFarland, 2001). 
 
PTP incidence were reported to be 1 in 50,000 – 100,000 transfusion (Metcalfe, 2004) and were 
found more in middle age female rather than man. The simple explanation was due to the previous 
sensitization by multiple pregnancy (Shtalrid et al., 2006). However, in an 11 years of retrospective 
study done by Shtalrid and colleagues in 2006 from their working hospital, the incidence were 
found to be 1 : 24,000 transfusion, implicated in 4 women and two men. The big difference in 
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incidence is maybe due to the potential misdiagnosis of PTP since the critically ill patient usually 
have alternative explanation for thrombocytopenia (Shtalrid et al., 2006) and the lack of 
confirmatory laboratory data to rule out the alternative reason for the low platelet count 
(Roubinian and Leavitt, 2015). Furthermore, the distribution of HPA-1bb phenotype is also a factor 
that stimulate the acquisition of this disorder. In a cohort study done by (Menis et al., 2015), they 
found out that there is no association of sex with incidence of PTP. Since PTP is primarily due to 
the previous exposure of platelet alloantigen, men and women with previous history of transfusion 
is also at risk. Therefore sex should not be a factor for suspecting a PTP  (Roubinian and Leavitt, 
2015).  Since PTP can destruct the allogenic platelet as well as autologous, platelet transfusion 
may not be beneficial. Administration with IVIG is the preferred therapy (Delicou and Bellia, 2015). 
 
 1.1.3.2 Neonatal alloimmune thrombocytopenia (NAIT) 
NAIT refers to a disorder that affecting foetal and neonatal. It happens when there is a 
fetomaternal incompatibility and is almost similar to the haemolytic disease of newborn (HDN). 
However, in NAIT, platelet is the target cell of destruction (Taaning, 2000), and it may occur in first 
pregnancy (Sachs, 2013, Carr et al., 2015). NAIT happens when the foetus inherited platelet 
antigen from the father which absent on the mother’s platelet. Upon sensitization, mother will 
produce IgG platelet alloantibody and this antibody are capable to travel through the placenta, 
recognizing the specific platelet on the foetal antigen thus destroy it. The clearance of the 
antibody-coated platelet will lead to low platelet count thus increasing the chance of spontaneous 
bleeding in utero or after delivery. The symptom can vary from asymptomatic through incidental 
findings of thrombocytopenic condition to severe life-threatening situation such as intracranial 
haemorrhage (Delicou and Bellia, 2015). Platelet production in the fetus begin around 5 weeks 
after conception and reach normal postnatal range of 150 – 450 x 109/L by the end of second 
trimester (Carr et al., 2015), with major antigens are very well expressed at week 19 of gestation 
(Delicou and Bellia, 2015).  
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Figure 3 : Pathophysiology of neonatal alloimmune thrombocytopenia (NAIT) 
(Blanchette et al., 2000). 
 
 
 
In Caucasian, the incidence of NAIT was reported to be about 1 in 1000 deliveries (Bakchoul et al., 
2014). It has also been reported to be occurring in the Malaysian population (Armawai et al., 2014) 
in much smaller numbers. In Caucasians, about 75%  NAIT cases are induced by anti-HPA-1a on 
GPIIIa, and another 15% of cases are caused by anti- HPA-5b on GPIIa (Sachs, 2013). Conversely, 
in Asian, predominantly in Japanese, the most frequently detected antibodies in NAIT are anti-
HPA-4b and anti-HPA-5b  (Kiyokawa et al., 2014). Although NAIT has been reported to be 
exclusively associated with the HPA antibodies, there are reports of anti-HLA associated with NAIT, 
but the evidence has been indirect and weak. Therefore, the correlation of NAIT and anti-HLA 
Class 1 remain a myth (Taaning, 2000). Nevertheless, HLA Class II determinants is said to have an 
association with HPA-1a alloimmunisation.  Similarly as in PTP, maternal immunization against 
HPA-1a is genetically linked to the presence of the HLA class II allele DRB3*01:01. Approximately 
90% of immunized women are DRB3*01:01 positive (Sachs, 2013).  Another report by Delicou and 
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Bellia also show that HPA-1a-negative women who have become sensitised to the HPA-1a antigen 
also possess the HLA-B8, HLA-DR3, and DR52a antigens. This lead to assumption that these alleles 
are markers for increase  risk of alloimmunisation (Delicou and Bellia, 2015).  
 
Thrombocytopenia and bleeding in neonate is the common sign of NAIT.  An extensive study 
done by (Mueller-Eckhardt et al., 1989a) shows that the most common bleeding signs is petechiae, 
haematoma and followed by melena (bloody stool). Haemoptysis, retinal bleeding and 
haematuria was also seen in some cases. These NAIT babies also were commonly observed  to 
have low birth weight (Sachs, 2013). Although thrombocytopenia is often temporary and resolves 
spontaneously, it can be severe with serious bleeding including intracranial haemorrhage 
(Bakchoul et al., 2014). This alarming  condition may resulted in persistent neurologic impairment 
and death (Blanchette et al., 2000).  Therefore, rapid management is needed with the primary 
goal is to stop or prevent bleeding from occurring, more importantly to prevent intracranial 
haemorrhage. Neonate should be transfused with negative-antigen platelet type to rapidly 
increase the platelet level count to 50 x 109/L. In situation where typed platelets are not available 
from random donor, compatible platelet can be obtain from the mother via platelet apheresis 
donation. Prior to transfusion,  platelet from mother must be washed to remove maternal plasma 
that contain the antibody which could prolong the thrombocytopenia. It also must be irradiated 
to prevent graft-versus-host-disease (GVHD) (Carr et al., 2015). High-dose intravenous 
immununoglobulin may also be used to prolong the survival of the autologous platelet (Bussel 
JB, 2009, C, 2008, Birchall JE, 2003).   In 2014, a study was done by Bakchoul and colleague, on 
the effect of IVIG that was administered together with random platelet transfusion. However, they 
did not observe any additional benefit from it. 
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 1.1.3.3 Platelet Transfusion Refractoriness (PTR) 
Refractoriness to platelet transfusion refers to the lack of response, by specifically looking at the 
post-transfusion count increment (Pavenski et al., 2012), after 2 consecutive platelet transfusion 
of adequate allogeneic platelet dose (Delaflor-Weiss and Mintz, 2000) of fresh, random donor 
ABO compatible platelets (Rebulla, 2005). Platelet refractoriness will result in a persistent 
thrombocytopenic condition due to the shortened survival of transfused platelet in the recipient’s 
blood circulation. To determine the efficacy of the platelet transfusion, post-transfusion count can 
be determined from two calculation formula; (1) corrected count increment (CCI) in relating it to 
the patient’s body surface area or (2) percent platelet recovery (PPR) in the context of estimated 
blood volume of the patient (Wood et al., 2005, Delaflor-Weiss and Mintz, 2000, Davis et al., 1999).               
Each formula compares the incremental change of platelet count from the initial in relative to the 
dose of platelet transfused in the first hour, and after 18 to 24 hours.   The calculation formula are 
as in table 1.1 
 
 
Table 1.1  : Calculation formula for measurement of platelet transfusion efficacy and value 
suggestive of refractoriness 
Measures of 
transfusion outcome 
Formula Value suggestive of 
refractoriness 
Corrected count 
increment (CCI) 
ACI  x body surface area (m2) 
No of platelet transfused x 1011 
At 10 – 60 min, CCI <7,500/uL 
At 18 – 24 hrs, CCI <5,000/uL 
Percent platelet 
recovery (PPR) 
ACI x total blood volume x 100% 
No of platelet transfused x 1011 
At 10 – 60 min, PPR <20 % 
At 18 – 24 hrs, PPR < 10% 
Note : ACI (Absolute count increment) = (post-transfusion count/uL – pre-transfusion count/uL 
(Pavenski et al., 2012) 
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Platelet refractoriness can be immune or non-immune cause (Pavenski et al., 2012, Delaflor-Weiss 
and Mintz, 2000). The non-immune cause can be due to the platelet product itself, such as poor 
platelet quality and old aged platelet (Delaflor-Weiss and Mintz, 2000) or due to the clinical 
condition of the patient that accelerated with platelet consumption such as splenomegaly, 
disseminated intravascular coagulopathy (DIC), bone marrow transplant and graft versus host 
disease (GVHD) (Ishida et al., 1998, Bishop et al., 1991, Slichter, 1990, Bishop et al., 1988). It 
contributed to more than 80% of all refractory cases. Conversely, immune-mediated platelet 
refractory is only about 20% of all the refractory cases, with majority of it is due to the 
alloimmunization of HLA, followed by HPA, or both HLA and HPA (Pavenski et al., 2012). The ABH 
antibodies also have been reported to cause immune refractoriness (Hod and Schwartz, 2008, 
Laundy et al., 2004) especially in the high expresser platelet. These antibodies that directed toward 
the specific antigen of HLA, HPA and ABH are called platelet reactive antibodies and is the cause 
for accelerated platelet destruction and transfusion failure (Agarwal et al., 2014). PTR is commonly 
associated with multiple platelet transfusion. Despite of receiving multiple episode of platelet 
transfusion, high number of haematological patient were reported to develop immune refractory 
to platelet transfusion even after receiving single episode of multiple RBC transfusion (Rebulla, 
2005). 
 
The 1-hour CCI or PPR count may help in establishing the cause of refractoriness. Commonly, 
there will be no increment in the 1-hour count for immune refractory, as compared to the non-
immune cause where it will be normal during the 1-hour count but reduced at 18-24 hours count  
(Craig H. Fletcher, 2015, Delaflor-Weiss and Mintz, 2000), with exception to splenomegaly. In 
platelet refractory management, evaluation of the clinical condition refractory pattern is vital to 
discriminate the type of refractoriness. While management approach of non-immune cause is 
simply by treating the underlying cause, managing patients with immune-mediated platelet 
refractoriness can be very challenging (Lee and Ayob, 2015). 
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1.1.4 Support for the platelet refractoriness patient 
When a patient was discovered for persistent thrombocytopenia following two good quality of 
platelet transfusion, he will be further evaluated to identify the source of refractory. While the 
management of non-immune platelet refractoriness is mainly depending on treating the 
underlying illness (Stolla et al., 2015), the immune platelet refractoriness is usually managed by 
transfusion of matched platelets (Pavenski et al., 2012).  
 
 
 1.1.4.1 Antigen-negative, HLA matched and epitope matched 
Through an antibody identification test, offending antibody type that cause refractoriness to the 
patient can be identified. Once it has been identified, a negative-antigen-platelet toward the 
corresponding antibody will be search from the inventory stock by phenotyping process or by 
checking through the donor registry from the donor pool. In this scenario, patient genotyping is 
not really necessary, and platelet can be issue without crossmatch. Conversely, in patient that is 
highly sensitized with multiple antibody, or need long term platelet support, the patient’s sample 
will be tested for HLA typing. If the refractory is due to anti-HPA, HPA typing will also be 
performed. While waiting for the result that could take for days, ABO compatible fresh platelet is 
given to support the thrombocytopenic condition (Wiita and Nambiar, 2012). To supply platelet 
based on this HLA match approach, the donor and patient must be identical for ABO group and 
all four locus of HLA-A and HLA-B or BU (level of mismatch) match grade where the donor and 
recipient are identical at only two or three locus. If the refractory is due to HPA, the donor and 
recipient must be identical for HPA too (Lee and Ayob, 2015, Kopko et al., 2015).  
 
Another methodology of finding a match platelet for HLA-refractory patient is through epitope-
based matching. Epitope are composed of a short linear sequence or discontinuous amino acid 
residues that form a cluster on a molecular surface (Duquesnoy and Askar, 2007). Patient will only 
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make antibodies to foreign epitopes. Thus, instead of matching for full HLA type, matching of 
epitope can be done by using a “HLA-matchmaker” software.  
 
Through any of these methodologies, the ideal platelet donor that have a match-HLA or minor 
mismatch-HLA will be called upon to donate and the platelet will be issued to the specific patient 
(Silva et al., 2010, Bub et al., 2013). However, the real challenges are due to the HLA type itself.  
HLA is very polymorphic as compared to HPA, thus defies the management of the refractory 
patient through these approaches. The HLA-typed donor pool must be large enough to increase 
the chance of finding an ideal match (Petz et al., 2000) but the platelet may not necessary be 
crossmatched prior to issuing it to the patient. Once donor is identified through the registry, donor 
will be called upon for donation. Even it seems easy, this may take few days for the donor to turn 
up to the blood centre and donate. 
 
 
1.1.4.2 Platelet crossmatch 
Crossmatch is theoretically more sensitive than the HLA match owing to its capability to detect 
any platelet reactive antibodies, including the anti-glycoprotein which can be found in the 
autoimmune thrombocytopenic disorder. While HLA matching approach is time consuming, 
crossmatch can be done in few hours upon receiving the patient’s serum. It provide rapid supply 
of compatible blood and often the choice of a blood centre that don’t have large registry of typed 
HLA profile. Furthermore, crossmatch can be done with ABO-compatible blood, and platelet can 
be supplied before completing the HLA antibody and HLA genotyping of the patient. However, 
this test is suitable for patient with low to moderate immunization to HLA Class 1 antibody. In 
patient who is highly sensitized to the HLA antigens, crossmatch will not be easy, as it will be 
difficult to find a compatible unit (Kopko et al., 2015). 
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Platelet crossmatch can be performed either by solid phase red cell adherence (SPRCA) assay or 
by flow cytometry. It is crucial that in crossmatching, any incompatibility due to platelet reactive 
antibody including the ABH, HPA and HLA system can be detected. In SPRCA assay, the intact 
platelet from the donor is bound to the U-shape microplate well by a coating monoclonal 
antibodies. Patient serum is added in and incubated to allow for antigen-antibody interaction. 
When the incubation is over, the microplate well is washed to remove any unbound antibody, 
followed by adding an indicator RBC that is coated with anti-human globulin (AHG). Sample is 
then centrifuged and result will be analysed. If the patient sample contain any platelet reactive 
antibody, the red cell indicator will form a monolayer spread over the well, however, if the reaction 
is negative, the indicator red cell will be pelleted at the bottom of the well.  
 
SPRCA-based-assay is also commercially available. Capture-P® by IMMUCOR, USA has been used 
by the blood centres of the pacific reference laboratory in San Francisco, USA (Wiita and Nambiar, 
2012), while MASPAT, Sanquin Blood Supply, Amsterdam, are the choice of many researchers for 
crossmatching (Salama et al., 2014, Schallmoser et al., 2006, Jia et al., 2014). 
 
Another approach for crossmatching is by using flow cytometry assay. The test is called platelet 
immunofluorescence testing or PIFT. In PIFT, intact donor platelet is incubated with patient serum. 
After incubation, the tube are washed to remove any unbound antibodies, followed by adding a 
fluorescence-labelled-anti human IgG (FITC-IgG) and incubated again for the reaction to take 
place. Next, the mixture is washed again to remove the excess unbound FITC-IgG and the result 
will be ready to be analysed by flow cytometer.  
 
The principle and result interpretation of PIFT and SPRCA will be illustrated in figure 12 until figure 
15 at page 60 and 63. 
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Crossmatch-compatible platelets are presumed to be lacking the antigen which the antibody 
present, while incompatible crossmatch is presumed to possess the antigen in which reacting with 
the clinically significant antibody in the patient. The incompatible result will predict a poor 
response in over 90% of transfusion. Conversely, a compatible crossmatch in an in vitro testing 
does not guarantee good survival of the transfused platelet in vivo. Compatible crossmatch is 
predictive to be successful in about 50-60% of the transfusion (Marwaha and Sharma, 2009).  
While it does not promise an improved platelet count, crossmatch does improve on the availability 
of the platelet for the patients where platelet can be obtain without the need to do HLA and HPA 
typing to the patient.  Donor and many platelet can be crossmatch simultaneously in a rapid time 
frame (Craig H. Fletcher, 2015).  
 
Each methodologies on supplying platelet to the immune-mediated thrombocytopenic patient 
have its own strength and weakness, hence, single approach might not be good enough. 
Depending on the clinical diagnosis of the patient, some large blood transfusion service may 
combine all approach ;  antigen-negative, HLA-matching and crossmatch in order to provide the 
best platelet product to the immune-mediated thrombocytopenic patient (Marwaha and Sharma, 
2009). 
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1.2 Problem statement 
Various strategies have been developed in order to support platelet crossmatch for 
alloimmune-mediated thrombocytopenic patient. Some approaches have been described in 
paragraph 1.1.4.  Other therapies include the drug usage for immunosuppression, rituximab, 
intravenous immunoglobulin (IVIG), plasma exchange and immunoadsorption have also been 
tried but with little success  (Agarwal et al., 2014). In Malaysia, the management of 
thrombocytopenic patients who are refractory to random platelet transfusion continues to be 
in dilemma. National Blood Centre (NBC) is the only institution that offers the platelet antibody 
testing in the country, hence, it is the only centre that is capable of doing the platelet crossmatch 
test.  
 
While it sound simple, the setback of the platelet crossmatch procedure was actually the choice 
of the method itself. There are two different categories of testing. Glycoprotein-capture-based 
assay is a very sensitive and specific assay. However, it is not suitable for crossmatching because 
it test specifically on the glycoprotein of interest, and way too expensive. The example of this 
type of assay is the monoclonal alloantibody immobilization of platelet antigen (MAIPA). The 
other group of method is the intact-platelet-based assay, which will detect the antibody toward 
antigens presented on the platelet surface, including the ABH antigens. Therefore it is more 
suitable for the application in crossmatching. The example of this type of assay are the Solid 
Phase Red Cell Adherence Assay (SPRCA) and Platelet Immunofluorescence Assay (PIFT). 
 
In NBC, platelet immunology testing are done by both MAIPA and SPRCA assay. However, due 
to the principle of intact-platelet-based-assay, SPRCA is the more suitable method for platelet 
crossmatching process. It is a procedure that requires manual preparation of in-house reagents, 
manual testing, manual interpretation and manual result documentation (not computer-
generated-evidence-based result). This fully manual processes may give chance to bias as 
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competency of operator becomes an important confounding factor. Furthermore, SPRCA assay 
must be tested in batch due to the protocol that utilize microtiterplate with coated capture 
antibody on the base of the microplate well.  The maximum crossmatch per batch can be up to 
45 crossmatches. Even though it can be used for a much smaller numbers, single crossmatch 
seems impractical when relating it to cost, laboriousness, and time taken to complete the test. 
Therefore, due to the difficulties and nature of test that requires highly technical skilled 
personnel, this test is only offered at the NBC, where staff performance being supervised and 
competency is regularly assessed and monitored. 
 
Eventhough SPRCA works well as a crossmatch protocol, the biggest limitation of SPRCA is that 
it is not suitable for single crossmatching. Single crossmatch is important when it comes to 
checking the compatibility of the patient with a specific and single apheresis donor. As the cost 
of the apheresis product is very expensive and continue to increase each year, it is better to 
ensure that the plateletpheresis unit is compatible toward the immune-mediated 
thrombocytopenic recipient in order to avoid wastage and unbeneficial transfusion. Apart from 
that, single donor platelet transfusion may reduce the risk of septic transfusion reaction (Ness 
et al., 2001). Hence, by looking into all the limitations of the current available method, and by 
considering the need for intensive medical support in terms of transfusing compatible platelet 
to the alloimmune-mediated thrombocytopenic patient, there is an essential need to search for 
an enhance protocol that can overcome the limitation of SPRCA. Moreover, the new method 
should be feasible to be adopted by other blood transfusion centre in this country. Therefore, 
this study is conducted to evaluate the qualitative value and feasibility of PIFT as a tool for 
platelet crossmatch testing, in order to heighten the service for provision of compatible platelet 
supply for the immune-mediated thrombocytopenic patient in Malaysia. 
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1.3 Research Objectives 
1.3.1 General objectives 
To evaluate the qualitative performance of PIFT for platelet crossmatching and 
analyse the feasibility of the assay as a tool for the provision of compatible 
platelet supply to the immune-mediated thrombocytopenic patient. 
 
1.3.2 Specific objectives 
1.3.2.1 To optimize PIFT by evaluating the most optimal FITC-IgG dilution that 
work best in PIFT 
1.3.2.2 To measure the sensitivity, specificity, result predictive value and false 
positivity rate of the PIFT assay. 
 
 
 
1.4 Research question 
Does PIFT have a good qualitative performance for platelet crossmatch test, can it 
overcome the limitation of SPRCA and is it feasible to be implemented in the blood bank 
for platelet crossmatch service? 
 
 
1.5 Hypothesis 
 
HO     :     PIFT assay is a depreciate protocol with poor qualitative value, and it is not 
feasible to be implemented for platelet crossmatch service 
 
2  
HA      :     PIFT assay is an enhance protocol with good qualitative value and it is feasible 
to be implemented for platelet crossmatch service 
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1.6 Flowchart 
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Chapter 2 
MATERIALS AND METHODOLOGY 
 
2.1 Introduction 
“Platelet Crossmatch By Flow Cytometry : Evaluation and Feasibility Study”  is an applied 
research in searching for an enhanced protocol for blood bank service application. This research 
is carried out in National Blood Centre (NBC) specifically in the Platelet and Haematology 
Laboratory. PIFT protocol was adopted from the National Institute for Biological Standards and 
Control (NIBSC) website http://www.nibsc.org/science_and_research/biotherapeutics/platelets. 
aspx. The assay was then optimized in local laboratory setting, in order to establish the best FITC-
IgG dilution by using known remaining serums donated by the Platelet Laboratory, NBC.                  
Once PIFT has successfully optimized, qualitative evaluation were then carried out. 
 
In this qualitative study, 20 voluntary donors were randomly selected. These donors were 
genotyped for their HPA profile. Platelet crossmatch is done on batch of control serum that have 
either HPA-antibodies with known specificity, HLA-antibodies with unknown specificity, serum 
with no antibodies, and serum with specificity toward the glycoprotein itself (autoantibody). The 
result of the crossmatch will then be compared to the HPA genotype profile of the donor that will 
serve as a base to infer a true positive and true negative result. However, for control serum with 
HLA-antibody, the result can only be interpreted for absolute compatibility result, but not for 
qualitative analysis because the information on the antibody specificity is not obtainable. This part 
will be elaborated in Chapter 4 – limitation of study.  
 
In this study, reagents are commercially purchased, or otherwise stated. The details of the reagents 
are listed in appendix 2. 
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2.2 Platelet donor recruitment 
20 donors were involved in this study. Sampling were made randomly from group O RhD positive 
voluntary platelet apheresis donor that donates at Pusat Darah Negara, Kuala Lumpur, via walk-
in donation. Samples were collected from 25th February 2015 to 17th March 2015 and informed 
consent was obtained. All donors were given a unique identification number, known as “Panel ID” 
for the purpose of this study. Ethical clearance have been granted from National Medical Research 
Register (NMRR) of Ministry of Health (MOH). Reference number is NMRR-14-1293-23185 (IIR). 
 
2.2.1 Inclusion and exclusion criteria 
Platelet apheresis donor were recruited from donors that are eligible to donate at the time of 
donation. The eligibility of donation are as described in Transfusion Practice Guidelines for 
Laboratory Personnel, 3rd edition, 2008. All donors were screened for HIV, Hepatitis B, Hepatitis C 
and Syphilis with serology screening and nucleic acid testing to ensure that the blood product 
and blood samples is free from pathogen that could jeopardize the safety of individual that may 
be in contact with the sample.  
 
 
 2.2.2 Blood sampling process 
Venous blood samples were collected from donor’s vein before the apheresis donation 
commence. Blood were drawn into 6ml K2.EDTA tube without gel, and mixed gently to ensure 
that the anticoagulant homogenized with the blood to avoid clotting. All tubes were then labelled 
with Panel ID for identification of sample and were sent to the Platelet Laboratory. There, the 
sample is further processed for DNA extraction as described in paragraph 2.2.3, and for 
preparation of platelet suspension as described in paragraph 2.5.3 at page 33. 
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2.3 Platelet Donor - DNA extraction 
DNA extraction was performed by using commercial DNA extraction kit (ExgeneTM Blood SV Mini, 
GeneAll®, South Korea). All reagents, buffers (BW, TW and AE) and spin column used in this process 
are part of the kit, with exception to the absolute ethanol and microtubes. 
 
 To start the DNA extraction process, the donor’s whole blood sample from 2.2.2 was centrifuge 
at 4,000g for 10 minutes. After centrifuging, 3 distinctive layers of plasma, buffy coat and pack 
cells can be easily identified. 200ul of blood sample which contain large amount of the buffy coat 
layer was transferred to a 1.8ml-sized microtube, follow by the addition of 20ul of Proteinase K. 
The mixture was gently vortex to mix the solution. Next, 200ul of BL buffer was added into the 
tube, followed by a vigorous vortex until the colour of the sample change to black-brown which 
indicate cell lysis. Sample was then incubated at 56°C for 10 minutes.  
 
After incubation, 200ul of absolute ethanol was added to mixture followed by a strong vortex. 
Clot may form at this phase. The content of the microtube was then carefully transferred to a spin 
column with attempt to avoid transferring the clot as it may clogged the spin column. The spin 
column was then centrifuged at 13,000rpm for 3 minutes. Once the centrifuging stop, the flow-
through is discarded and the spin column is inserted into a new-clean collection tube. 500ul of 
BW buffer is added into the same spin column and was centrifuged again at 13,000rpm for 
another 3 minutes. Once the centrifuging stop, the clarity of the flow-through and spin column is 
examine by visual inspection. If there are still residual of brownish colour remain, repeat the 
washing with BW buffer until clear, and proceed to the next step with a new-clean collection tube. 
 
Next, 700ul of TW buffer was added into the spin column, followed by centrifugation of the spin 
column at 13,000rpm for 3 minutes. The flow-through was discarded and the same collection tube 
was re-inserted back into the spin column, followed by another centrifugation for 3 min at 
